Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 116

1.

A descriptive study of patients receiving foundational financial assistance through local specialty pharmacies.

Zhu J, Odebralski R, Boghani S, Walley C, Koen F, Conley C, Kirkham HS.

Am J Manag Care. 2018 Mar;24(5 Suppl):S80-S84.

2.

Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy.

Jia H, Thelwell C, Dilger P, Bird C, Daniels S, Wadhwa M.

Thromb Res. 2018 Mar;163:105-116. doi: 10.1016/j.thromres.2018.01.039. Epub 2018 Feb 6.

3.

Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort.

Lebrun D, Hentzien M, Cuzin L, Rey D, Joly V, Cotte L, Allavena C, Dellamonica P, Servettaz A, Bani-Sadr F; the Dat’AIDS study group.

AIDS. 2017 Sep 24;31(15):2159-2166. doi: 10.1097/QAD.0000000000001603.

PMID:
28723711
4.

Retinopathy, Interferon .

Feroze KB, Wang J.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2017 Oct 6.

5.

Novel aspects of defensins' involvement in virus-induced autoimmunity in the central nervous system.

Kazakos EI, Kountouras J, Polyzos SA, Deretzi G.

Med Hypotheses. 2017 May;102:33-36. doi: 10.1016/j.mehy.2017.02.020. Epub 2017 Mar 6.

PMID:
28478826
6.

Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review.

Kundra A, Wang JC.

Crit Rev Oncol Hematol. 2017 Apr;112:103-112. doi: 10.1016/j.critrevonc.2017.02.011. Epub 2017 Feb 17. Review.

PMID:
28325251
7.

Chitin and chitinase: Role in pathogenicity, allergenicity and health.

Patel S, Goyal A.

Int J Biol Macromol. 2017 Apr;97:331-338. doi: 10.1016/j.ijbiomac.2017.01.042. Epub 2017 Jan 16. Review.

PMID:
28093332
8.

Pharmaceutical Approval Update.

Kaufman MB.

P T. 2016 Oct;41(10):617-639.

9.

Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.

Tagawa A, Ogawa T, Tetsuka S, Otsuka M, Hashimoto R, Kato H, Ando K, Tanabe H.

Mult Scler Relat Disord. 2016 Sep;9:155-7. doi: 10.1016/j.msard.2016.08.003. Epub 2016 Aug 5.

PMID:
27645365
10.

Interferon Beta: From Molecular Level to Therapeutic Effects.

Haji Abdolvahab M, Mofrad MR, Schellekens H.

Int Rev Cell Mol Biol. 2016;326:343-72. doi: 10.1016/bs.ircmb.2016.06.001. Epub 2016 Jul 20. Review.

PMID:
27572132
11.

The redesign of consumer cost sharing for specialty drugs at the California Health Insurance Exchange.

Robinson J, Price A, Goldman Z.

Am J Manag Care. 2016 Mar;22(4 Suppl):s87-91.

12.

Toll-Like Receptor 2 Modulates the Balance of Regulatory T Cells and T Helper 17 Cells in Chronic Hepatitis C.

Liu X, Guan JH, Jiang BC, Li ZS, Zhu GZ.

Viral Immunol. 2016 Jul-Aug;29(6):322-31. doi: 10.1089/vim.2016.0013. Epub 2016 Apr 15.

PMID:
27082819
13.

Neurologic Complications of Human Immunodeficiency Virus Infection.

Nath A.

Continuum (Minneap Minn). 2015 Dec;21(6 Neuroinfectious Disease):1557-76. doi: 10.1212/CON.0000000000000244. Review.

PMID:
26633776
14.

Multiple Sclerosis Like Condition in a Patient of Hepatitis C after Treatment with Interferon Alpha: A Case Report.

Fazil PA, Ali SM, Zaboli M, Shah SR.

J Clin Diagn Res. 2015 May;9(5):OD14-5. doi: 10.7860/JCDR/2015/12588.5962. Epub 2015 May 1.

15.

Sclerosed Hemangioma Accompanied by Multiple Cavernous Hemangiomas of the Liver.

Yuki M, Emoto Y, Kinoshita Y, Yoshizawa K, Yuri T, Tsubura A.

Am J Case Rep. 2015 Jun 27;16:401-5.

16.

Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis.

Gibbons E, Promislow S, Davies RA, Chandy G, Stewart DJ, Vladamir CD, Pugliese C, Dunne R, Mielniczuk LM.

Can Respir J. 2015 Sep-Oct;22(5):263-5. Epub 2015 Jun 17.

17.

Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders.

Belendiuk KA, Baldini LL, Bonn-Miller MO.

Addict Sci Clin Pract. 2015 Apr 21;10:10. doi: 10.1186/s13722-015-0032-7. Review.

18.

Recombinant glucagon: a differential biological activity.

Basso AM, Pelegrini PB, Mulinari F, Costa MC, Viana AB, Silva LP, Grossi-de-Sa MF.

AMB Express. 2015 Mar 12;5:20. doi: 10.1186/s13568-015-0099-2. eCollection 2015.

19.

Co-existence of tumefactive MS and hepatitis C: A need for further screening and new therapeutic challenge.

McGee J, Minagar A.

J Neurol Sci. 2015 Feb 15;349(1-2):1-2. doi: 10.1016/j.jns.2014.12.033. Epub 2015 Jan 3. No abstract available.

PMID:
25592413
20.

Tumefactive multiple sclerosis and hepatitis C virus 2a/2C infection: Dual benefit of long-term interferon beta-1a therapy?

Mader EC Jr, Richeh W, Ochoa JM, Sullivan LL, Gutierrez AN, Lovera JF.

J Neurol Sci. 2015 Feb 15;349(1-2):239-42. doi: 10.1016/j.jns.2014.12.034. Epub 2015 Jan 3.

PMID:
25575859

Supplemental Content

Loading ...
Support Center